The landscape of obesity treatment is undergoing a significant transformation, particularly for adolescents and young adults
These statistics underscore a rapid transformation in obesity care for youths, with pharmacotherapy now frequently serving as the initial intervention, moving away from surgical approaches as the primary first-line treatment for many
Last month, the Massachusetts Center for Health Information and Analysis reported that health care spending climbed 8.6 percent to $78.1 billion in 2023, more than double the states 3.6 percent annual growth benchmark
doi: 10.2337/db21-0848 Summary Keywords GLP-1 - glucagon-like peptide-1, GIP - glucose-dependent insulinotropic peptide, obesity, incretin, pharmacology Citation Douros JD, Flak JN and Knerr PJ (2025) The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP